Checkpoint Inhibitors in Malignant Pleural Mesothelioma
0 意见
• 07/02/23
0
0
嵌入
Mark Socinski, MD; Mary Jo Fidler, MD; Roy Herbst, MD, PhD; Geoffrey Oxnard, MD; and Naiyer Rizvi, MD discuss the potential for checkpoint inhibitors, such as pembrolizumab, for malignant mesothelioma. Also discussed is the importance of trials that can be done in the community setting.
显示更多
脸书评论
SORT BY-
热门评论
-
最新评论